High-Value Turnover and Volume Surge
On 20 August 2026, Strides Pharma Science recorded a total traded volume of 15,61,526 shares, translating into a substantial traded value of ₹161.88 crores. This level of turnover places the stock among the top equity performers by value on the trading day. The stock opened at ₹986.5, marking an 8.07% gap up from the previous close of ₹957.5, and reached an intraday high of ₹1,056.0, representing a 9.15% rise from the prior session’s close. The last traded price (LTP) stood at ₹1,028.3 as of 09:44 IST, reflecting a day change of 6.48%.
Such elevated trading activity is indicative of strong demand and liquidity, with the stock’s delivery volume on 19 August rising by 100.96% compared to its five-day average, reaching 1.85 lakh shares. This surge in delivery volume suggests increased investor conviction and participation beyond short-term speculative trades.
Outperformance Against Sector and Market Benchmarks
Strides Pharma Science has outperformed the Pharmaceuticals & Biotechnology sector by 8.64% on the day, while the sector itself posted a modest 0.26% gain. The benchmark Sensex rose 0.52%, underscoring the stock’s relative strength amid broader market stability. Over the past two trading sessions, the stock has delivered a cumulative return of 9.95%, signalling sustained buying momentum.
Technically, the stock is trading above its 5-day, 20-day, and 200-day moving averages, which is a positive indicator of short- and long-term strength. However, it remains below the 50-day and 100-day moving averages, suggesting some resistance levels yet to be overcome for a more sustained uptrend.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Institutional Interest and Market Capitalisation Context
Strides Pharma Science is classified as a small-cap company with a market capitalisation of approximately ₹8,802 crores. Despite its relatively modest size compared to large-cap peers, the stock has attracted notable institutional interest, as evidenced by the sharp increase in delivery volumes and value traded. This suggests that fund managers and large investors are positioning themselves in anticipation of favourable developments or sector tailwinds.
The company operates within the Pharmaceuticals & Biotechnology industry, a sector that continues to garner investor attention due to its defensive characteristics and growth potential amid evolving healthcare demands. The recent upgrade in the company’s Mojo Grade from Sell to Hold on 27 July 2026, with a current Mojo Score of 57.0, reflects an improved outlook based on MarketsMOJO’s comprehensive analysis framework. This upgrade signals a cautious but positive reassessment of the company’s fundamentals and near-term prospects.
Price Momentum and Technical Signals
The stock’s price action today demonstrates strong momentum, with a notable gap-up opening and a sustained rally through the morning session. The intraday high of ₹1,056.0 represents a significant resistance test, while the day’s low of ₹985.4 indicates a relatively tight trading range, underscoring controlled volatility. The stock’s ability to maintain levels above key short-term moving averages suggests that buyers remain in control.
Liquidity metrics further support the stock’s tradability, with the current trading volumes sufficient to accommodate trade sizes of up to ₹0.46 crore based on 2% of the five-day average traded value. This level of liquidity is attractive for institutional investors seeking to build or exit positions without excessive market impact.
Considering Strides Pharma Science? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Outlook and Investor Considerations
While Strides Pharma Science’s recent price performance and trading activity are encouraging, investors should weigh the stock’s current Hold rating and modest Mojo Score of 57.0 against the broader market context and sector dynamics. The upgrade from Sell to Hold indicates that while the company’s fundamentals have improved, it may still face challenges or uncertainties that warrant a cautious stance.
Investors should monitor upcoming corporate developments, quarterly earnings, and sector trends that could influence the stock’s trajectory. Additionally, the stock’s position below the 50-day and 100-day moving averages suggests that further confirmation of a sustained uptrend is needed before considering a more aggressive investment stance.
Given the stock’s small-cap status, volatility can be higher compared to large-cap peers, and liquidity, while adequate, may fluctuate. Institutional investors appear to be increasing their exposure, which could provide support, but retail investors should remain vigilant and consider risk management strategies.
Summary
Strides Pharma Science has demonstrated strong value-based trading activity on 20 August 2026, supported by institutional interest and positive technical momentum. The stock’s outperformance relative to its sector and the Sensex, combined with a recent upgrade in its Mojo Grade, highlights improving fundamentals and investor confidence. However, the Hold rating and technical resistance levels suggest a measured approach is prudent. Market participants should continue to track volume trends, price action, and sector developments to gauge the stock’s medium-term potential.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
